Peter Stein Takes Short Path To Director Of US FDA Drug Office
An industry veteran, Stein has been with agency for only two years; Bob Temple becomes powerful OND "consultant."
You may also be interested in...
A Pink Sheet analysis illustrates how the outgoing commissioner enhanced FDA's ability to facilitate the further development of innovative drugs.
FDA's two recent advisory committee meetings at its White Oak campus offer no obvious clues that agency is struggling due to dwindling carryover balances and furloughed employees.
A departure date has yet to be determined for the associate director of therapeutic biologics, who helped negotiate and implement the biosimilar user fee program.